NOVARTIS AG
CIK 1114448 · last filed 2020-07-16
NOVARTIS AG is a corporate insider who has filed 46 SEC Form 4 insider transactions across 14 companies since 2008. The most recent filing, for PSTX, was dated Jul 16, 2020. Across all open-market trades the lifetime net is +$7.6M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.31B across reported positions. The firm reports its address in Basel, V8. 85 SEC filings were submitted jointly with Novartis Bioventures Ltd.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
NTLA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
BASEL, V8 CH 4056
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Poseida Therapeutics, Inc. (PSTX) Delisted | 10%+ Owner | 5,908,089 | $9.50 | $56.13M | $0 | 1 | 2020-07-16 |
| Akouos, Inc. (AKUS) Delisted | 856,262 | $13.29 | $11.38M | $4.25M | 1 | 2020-07-02 | |
| Galera Therapeutics, Inc. (GRTX) Delisted | 10%+ Owner | 17,448 | $17.60 | $307.1K | -$729.4K | 2 | 2020-06-12 |
| Whitehawk Therapeutics, Inc. (ARPO) Delisted | 10%+ Owner | 346,207 | $33.00 | $11.42M | -$695.9K | 2 | 2019-04-05 |
| Rein Therapeutics, Inc. (ALRN) Delisted | 10%+ Owner | 121,739 | $2.11 | $256.9K | $7.47M | 6 | 2018-08-16 |
| ALT | 10%+ Owner | 186,579 | $2.23 | $416.1K | $0 | 4 | 2018-06-15 |
| NTLA | 10%+ Owner | 4,129,903 | $11.65 | $48.11M | -$45.74M | 3 | 2017-12-14 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | 10%+ Owner | 2,307,877 | — | — | $781.6K | 4 | 2017-06-12 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | 10%+ Owner | 92,437 | $12.01 | $1.11M | $6.00M | 1 | 2016-04-12 |
| KINETA, INC./DE (PTI) Delisted | 10%+ Owner | 74,940 | — | — | $6.00M | 1 | 2016-02-17 |
| Eledon Pharmaceuticals, Inc. (TKAI) Delisted | 10%+ Owner | 502,765 | — | — | $5.56M | 5 | 2015-07-15 |
| IDENIX PHARMACEUTICALS INC (IDIX) Delisted | 33,185,191 | — | — | $10.23M | 9 | 2011-04-13 | |
| Adhera Therapeutics, Inc. (MRNAD) Delisted | 10%+ Owner | 2,804,670 | — | — | -$619.8K | 3 | 2011-01-25 |
| ALNY | 10%+ Owner | 5,602,898 | $225.10 | $1.26B | $15.11M | 3 | 2010-04-26 |
Recent Filings
46 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-07-16 | Poseida Therapeutics, Inc. (PSTX) Delisted | Conv (C) | +11,816,178 | $0 | EDGAR |
| 2020-07-02 | Akouos, Inc. (AKUS) Delisted | Mixed | +2,362,516 | $4.25M | EDGAR |
| 2020-06-12 | Galera Therapeutics, Inc. (GRTX) Delisted | Sell (S) | −34,464 | -$321.6K | EDGAR |
| 2020-06-09 | Galera Therapeutics, Inc. (GRTX) Delisted | Sell (S) | −42,622 | -$407.8K | EDGAR |
| 2019-04-05 | Whitehawk Therapeutics, Inc. (ARPO) Delisted | Sell (S) | −261,188 | -$258.5K | EDGAR |
| 2019-04-02 | Whitehawk Therapeutics, Inc. (ARPO) Delisted | Sell (S) | −463,526 | -$437.4K | EDGAR |
| 2018-08-16 | Rein Therapeutics, Inc. (ALRN) Delisted | Sell (S) | −11,870 | -$26.2K | EDGAR |
| 2018-08-06 | Rein Therapeutics, Inc. (ALRN) Delisted | Sell (S) | −9,404 | -$31.3K | EDGAR |
| 2018-07-31 | Rein Therapeutics, Inc. (ALRN) Delisted | Sell (S) | −16,916 | -$56.7K | EDGAR |
| 2018-07-27 | Rein Therapeutics, Inc. (ALRN) Delisted | Sell (S) | −40,794 | -$153.3K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.